Quarterly Activities/Appendix 4C Cash Flow Report

Invex Therapeutics Limited │ ABN 29 632 145 334│ Level 2, 38 Rowland St, Subiaco, Perth WA 6008 │ ASX / Media Release 22 January 2025 December Quarterly Activities Report & Appendix 4C Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Exenatide for neurological conditions relating to raised intracranial pressure (ICP), today provides an operational and corporate update to accompany its Appendix 4C cash flow statement for the quarter ended 3 1 December 2024 (Q2 FY25). Operational Update Exenatide Shows Improved Neuronal Cell Survival in a 3D Human Brain Model of Alzheimer’s Disease – Results of Tessara R&D Collaboration In August 2024, Invex entered into a Research Collaboration with Tessara Therapeutics (Tessara). The research examined the capacity of Exenatide to prevent cell death through an analysis of the therapeutic efficacy and safety of Exenatide on Tessara ’s Alzheimer’s Disease (AD) model, ADBrain™ neural micro-tissues. ADBrain™ models the Aß42-mediated neurodegeneration seen in AD. The data generated by the collaboration has yielded important new information for Invex as it relates to the applicability of Exenatide in alternative neurological diseases, including AD. This was the first time a GLP-1 receptor agonist (GLP-1RA), namely Exenatide has shown evidence of benefit in a three-dimensional human brain model in AD. Evidence is beginning to emerge that show GLP -1RAs may protect against AD dementia shrinking in the parts of the brain that control memory, learning, language and decision -making by up to 50%.1 Exenatide is within the same class of drug. Key Points of the data: • Low dose Exenatide shown to increase cell viability by approx. 24% versus controls under similar oxidative stress conditions experienced in AD patients leading to cell death • Moderate dose Exenatide resulted in a 45% increase in cell viability under conditions replicating ferraptosis, a distinct pathway of neuronal cell death and progression in AD • Exenatide was well tolerated by ADBrain™ micro-tissues over the dose range tested 1 https://aaic.alz.org/releases-2024/glp-drug-liraglutide-may-protect-against-dementia.asp Invex Therapeutics Limited │ ABN 29 632 145 334│ Level 2, 38 Rowland St, Subiaco, Perth WA 6008 │ 2 • Data consistent with emerging clinical evidence that GLP -1 receptor agonists (a class including Exenatide) may protect against AD dementia, a US$17 billion market in 20232 The Company plans to explore additional activities with Tessara that may provide additional new insights into the mechanism of action of Exenatide in AD and potential effects in other neurodegenerative diseases, including traumatic brain injury. Corporate Development The Company has held a number of productive discussions with a number of potential partners with complementary assets within the neurological field, or more generally that could generate additional pipeline opportunities and value for Invex shareholders. At this juncture, such discussions are not sufficiently developed to warrant further comment by the Company at this time and no binding commitments have been made in relating to any asset. Corporate Update 2024 Annual General Meeting The Company held its 2024 Annual General Meeting virtually on 26 November. All resolutions were passed by way of poll except for a single resolution pertaining to approval to issue securities to unrelated parties under an incentive plan . This approval was sought to allow Invex to issue securities to employees and consultants without utilising the Company’s placement capacity under Listing Rule 7.1. The objective of the Plan was to attract, motivate and retain key employees, contractors and other persons who provide services to the Company within a three year period. Financial Summary and Analysis The Company prudently managed its cash reserves during the quarter with R&D activities directed towards completing the research collaboration with Tessara . The Comp any closed the quarter with cash and cash equivalents of $5.8 million (Q1 FY25: $5.9 million), with overall operating cash outflows for the quarter of $0.12 million (Q1 FY25: $0.13 million). Cash outflows from operating expenditure included: • Payments for Research & Development expenditure for the quarter of $0.06 million (versus $0.015 million in Q 1 FY25) reflecting the commencement of the new collaboration with Tessara and regulatory payments associated with the Company’s IIH EVOLVE Phase III trial data storage with its Contract Research Organisation. • Administration and corporate costs of $0.12 million (versus $0.17 million in Q 1 FY25) the compliance costs associated with an ASX listed company, Director’s fees, audit and legal 2 Source; Grandview Research Invex Therapeutics Limited │ ABN 29 632 145 334│ Level 2, 38 Rowland St, Subiaco, Perth WA 6008 │ 3 costs. The Company continues to carefully control corporate overheads while it assesses new asset opportunities to complement the Company’s core Exenatide assets. Aggregate amounts paid to related parties of the Company and their associates included in the above costs were $82k for the quarter. Post Quarter Events On 20 January 2025, Invex announced the receipt of £114k (approximately A$0.22 million) to the Company’s wholly owned UK subsidiary from the UK government for eligible R&D expenditures made by Invex during the 2024 financial year. - ENDS - This release dated 22 January 2025 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics. For more information, please contact: Company/Investors Dr Thomas Duthy Executive Director [email protected] +61 402 493 727 Media Margie Livingston Ignite Communications [email protected] +61 438 661 131 To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter @InvexThera_ASX About Invex Therapeutics Ltd Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin ™. www.invextherapeutics.com. 45Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity Invex Therapeutics Ltd ABN Quarter ended (“current quarter”) 29 632 145 334 31 December 2024 Consolidated statement of cash flows Current quarter $A’000 Year to date (6 months) $A’000 1. Cash flows from operating activities - - 1.1 Receipts from customers 1.2 Payments for (62) (77) (a) research and development (b) product manufacturing and operating costs - - (c) advertising and marketing - - (d) leased assets - - (e) staff costs - - (f) administration and corporate costs (123) (281) 1.3 Dividends received (see note 3) - - 1.4 Interest received 59 116 1.5 Interest and other costs of finance paid - - 1.6 Income taxes paid - - 1.7 Government grants and tax incentives - 1.8 Other - - 1.9 Net cash (used in) operating activities (116) (242) 2. Cash flows from investing activities - - 2.1 Payments to acquire: (a) entities (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - Consolidated statement of cash flows Current quarter $A’000 Year to date (6 months) $A’000 (f) other non-current assets - - 2.2 Proceeds from disposal of: - - (a) entities (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - (f) other non-current assets - - 2.3 Cash flows from loans to other entities - - 2.4 Dividends received (see note 3) - - 2.5 Other (provide details if material) - - 2.6 Net cash from / (used in) investing activities - - 3. Cash flows from financing activities - - 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) 3.2 Proceeds from issue of convertible debt securities - - 3.3 Proceeds from exercise of options - - 3.4 Transaction costs related to issues of equity securities or convertible debt securities - - 3.5 Proceeds from borrowings - - 3.6 Repayment of borrowings - - 3.7 Transaction costs related to loans and borrowings - - 3.8 Dividends paid - - 3.9 Other – capital return - - 3.10 Net cash from / ( used in) financing activities - - 4. Net increase / (decrease) in cash and cash equivalents for the period 5,914 6,025 4.1 Cash and cash equivalents at beginning of period 4.2 Net cash from / (used in) operating activities (item 1.9 above) (116) (242) 4.3 Net cash from / (used in) investing activities (item 2.6 above) - - Consolidated statement of cash flows Current quarter $A’000 Year to date (6 months) $A’000 4.4 Net cash from / (used in) financing activities (item 3.10 above) - - 4.5 Effect of movement in exchange rates on cash held 8 23 4.6 Cash and cash equivalents at end of period 5,806 5,806 5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts Current quarter $A’000 Previous quarter $A’000 5.1 Bank balances 606 1,164 5.2 Call deposits 5,200 4,750 5.3 Bank overdrafts - - 5.4 Other (provide details) - - 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 5,806 5,914 6. Payments to related parties of the entity and their associates Current quarter $A'000 6.1 Aggregate amount of payments to related parties and their associates included in item 1 82 6.2 Aggregate amount of payments to related parties and their associates included in item 2 - Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments Relates to salaries, consulting and fees paid to Directors. Payments of $24,000 for company secretarial accounting and financial services to Concept Biotech of which Mr McAuliffe is a director and shareholder are included. 7. Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end $A’000 Amount drawn at quarter end $A’000 7.1 Loan facilities - - 7.2 Credit standby arrangements - - 7.3 Other (please specify) - - 7.4 Total financing facilities - - 7.5 Unused financing facilities available at quarter end - 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. 8. Estimated cash available for future operating activities $A’000 8.1 Net cash from / (used in) operating activities (Item 1.9) (6 months) (242) 8.2 Cash and cash equivalents at quarter end (Item 4.6) 5,806 8.3 Unused finance facilities available at quarter end (Item 7.5) - 8.4 Total available funding (Item 8.2 + Item 8.3) 5,806 8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1) 48 8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions: 1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: 2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: 3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. Date: 22 January 2025 Authorised by: Narelle Warren (On behalf of the Board of Directors) Notes 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so. 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report. 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity. 4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”. 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

The release as fetched from its publisher. weblink.com.au ↗